The main ingredient of megestrol tablets is megestrol acetate, which is indicated for the palliative treatment of advanced breast and endometrial cancer (i.e., recurrent, inoperable or metastasized patients). Megestrol tablets belong to a semi-synthetic progesterone derivative, whose mechanism of action is to control the development and growth of ovarian follicles through the effect on the secretion of pituitary gonadotropin, thus reducing the production of estrogen, so it has a certain inhibitory effect on some hormone-dependent tumors, such as late-stage breast cancer and endometrial cancer, but it can not replace the surgical, radiological or chemotherapeutic treatments. It should be noted that weight gain, constipation, nausea and vomiting, diarrhea, high blood pressure and other adverse reactions may occur during the administration of medroxyprogesterone tablets, which should be regulated under the guidance of a doctor to ensure the safety of medication.